Small cell carcinoma of the ovary, hypercalcemic type : model development and preclinical drug testing

...................................................................................................................... iii Lay Summary ............................................................................................................... v Preface......................................................................................................................... vi Table of

[1]  Tiffany G Sheu,et al.  Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach , 2018, Ecancermedicalscience.

[2]  S. Faria,et al.  Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review. , 2017, Current problems in diagnostic radiology.

[3]  J. Trent,et al.  The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type , 2017, The Journal of pathology.

[4]  P. Atadja,et al.  An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. , 2017, Nature chemical biology.

[5]  Mikkel A. Algire,et al.  The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. , 2017, Nature chemical biology.

[6]  Chao Lu,et al.  SWI/SNF complex in cancer , 2017, Nature Genetics.

[7]  E. Mekada,et al.  Reconstitution of a metastatic-resistant tumor microenvironment with cancer-associated fibroblasts enables metastasis , 2017, Cell cycle.

[8]  Wai Lim Ku,et al.  Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin , 2016, Nature Genetics.

[9]  Kathleen R. Cho,et al.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies , 2016, Nature Reviews Cancer.

[10]  A. Berchuck,et al.  The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases , 2016, Familial Cancer.

[11]  Jon R. Wilson,et al.  Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymp , 2016, Journal of medicinal chemistry.

[12]  I. Konishi,et al.  Immune checkpoint inhibition in ovarian cancer. , 2016, International immunology.

[13]  James T. Webber,et al.  Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib , 2016, Molecular Cancer Therapeutics.

[14]  J. Trent,et al.  The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. , 2016, Gynecologic oncology.

[15]  M. Leverkus,et al.  Crystal Violet Assay for Determining Viability of Cultured Cells. , 2016, Cold Spring Harbor protocols.

[16]  J. Ahringer,et al.  Comparative assessment of fluorescent proteins for in vivo imaging in an animal model system , 2016, bioRxiv.

[17]  R. Copeland,et al.  PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease. , 2016, Biochemistry.

[18]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[19]  J. Trent,et al.  Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type , 2015, The Journal of pathology.

[20]  M. Kool,et al.  Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor , 2015, Oncotarget.

[21]  Thomas P. Howard,et al.  SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.

[22]  F. Feuerhake,et al.  c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations , 2015, Oncotarget.

[23]  Chi-Ping Day,et al.  Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges , 2015, Cell.

[24]  J. Pritchard,et al.  Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors , 2015, Oncotarget.

[25]  B. Han,et al.  First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J. Trent,et al.  Abstract 5381: Therapeutic potential of HDAC inhibitors in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) , 2015 .

[27]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[28]  R. Eskander,et al.  Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer. , 2015, Recent patents on anti-cancer drug discovery.

[29]  Joshua M. Korn,et al.  Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors , 2015, Oncogene.

[30]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[31]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[32]  D. Goldenberg,et al.  In-Vivo Fusion of Human Cancer and Hamster Stromal Cells Permanently Transduces and Transcribes Human DNA , 2014, PloS one.

[33]  R. Siebert,et al.  SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis , 2014, Acta Neuropathologica.

[34]  W. Foulkes,et al.  No small surprise – small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour , 2014, The Journal of pathology.

[35]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[36]  Jason J. Corneveaux,et al.  Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 , 2014, Nature Genetics.

[37]  N. Schultz,et al.  Recurrent SMARCA4 mutations in small cell carcinoma of the ovary , 2014, Nature Genetics.

[38]  W. Hahn,et al.  ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.

[39]  C. Roberts,et al.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers , 2014, Proceedings of the National Academy of Sciences.

[40]  W. Hahn,et al.  Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation , 2014, Molecular and Cellular Biology.

[41]  Winnie S. Liang,et al.  Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) , 2014, Rare diseases.

[42]  W. Grajkowska,et al.  Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. a pilot study. , 2013, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[43]  K. Helin,et al.  Transcriptional regulation by Polycomb group proteins , 2013, Nature Structural &Molecular Biology.

[44]  J. Yokota,et al.  A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. , 2013, Cancer research.

[45]  D. Speicher,et al.  Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition , 2013, Cell cycle.

[46]  G. Crabtree,et al.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy , 2013, Nature Genetics.

[47]  R. Copeland,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[48]  R. Kingston,et al.  Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. , 2013, Molecular cell.

[49]  D. Huntsman,et al.  Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics , 2013, Orphanet Journal of Rare Diseases.

[50]  Jonathan R. Pollack,et al.  The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers , 2013, PloS one.

[51]  Giovanni Parmigiani,et al.  Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.

[52]  Jingyi Zhang,et al.  Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. , 2012, Biochemical and biophysical research communications.

[53]  D. Steinemann,et al.  A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type. , 2012, International journal of oncology.

[54]  L. Strukova,et al.  A monomeric red fluorescent protein with low cytotoxicity , 2012, Nature Communications.

[55]  M. Hung,et al.  The role of EZH2 in tumour progression , 2011, British Journal of Cancer.

[56]  X. Golay,et al.  A Comparison of Imaging Techniques to Monitor Tumor Growth and Cancer Progression in Living Animals , 2011, International journal of molecular imaging.

[57]  R. Kingston,et al.  Compaction of chromatin by diverse Polycomb group proteins requires localized regions of high charge. , 2011, Genes & development.

[58]  C. Roberts,et al.  SWI/SNF nucleosome remodellers and cancer , 2011, Nature Reviews Cancer.

[59]  R. Birge,et al.  Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. , 2011, Experimental hematology.

[60]  A. Bauer,et al.  Histone methylation by PRC2 is inhibited by active chromatin marks. , 2011, Molecular cell.

[61]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[62]  A. Chase,et al.  Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.

[63]  K. Münstedt,et al.  Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature , 2011, Archives of Gynecology and Obstetrics.

[64]  S. Orkin,et al.  Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.

[65]  H. Kajiyama,et al.  Identification and characterization of cancer stem cells in ovarian yolk sac tumors , 2010, Cancer science.

[66]  E. Nogales,et al.  Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription. , 2010, Progress in biophysics and molecular biology.

[67]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[68]  Keji Zhao,et al.  An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network , 2009, Proceedings of the National Academy of Sciences.

[69]  Kristin L. Hazelwood,et al.  Far-red fluorescent tags for protein imaging in living tissues. , 2009, The Biochemical journal.

[70]  G. Crabtree,et al.  Understanding the Words of Chromatin Regulation , 2009, Cell.

[71]  J. States,et al.  Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role , 2009, Journal of ovarian research.

[72]  Pallu Reddanna,et al.  Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. , 2008, Leukemia research.

[73]  J. Pearce,et al.  Advanced small cell carcinoma of the ovary in a seventeen‐year‐old female, successfully treated with surgery and multi‐agent chemotherapy , 2008, Pediatric blood & cancer.

[74]  F. Mayer,et al.  Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  I. Fidler,et al.  Murine models to evaluate novel and conventional therapeutic strategies for cancer. , 2007, The American journal of pathology.

[76]  Jonathan Flint,et al.  The genetic basis of emotional behaviour in mice , 2006, European Journal of Human Genetics.

[77]  Konstantin A Lukyanov,et al.  Fluorescent proteins as a toolkit for in vivo imaging. , 2005, Trends in biotechnology.

[78]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[79]  Colleen A Crane,et al.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[80]  R. Tsien,et al.  Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein , 2004, Nature Biotechnology.

[81]  E. Oliva,et al.  An Immunohistochemical Analysis of Ovarian Small Cell Carcinoma of Hypercalcemic Type , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[82]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[83]  Yi Zhang,et al.  Hierarchical recruitment of polycomb group silencing complexes. , 2004, Molecular cell.

[84]  M. Gore,et al.  Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Peter Choyke,et al.  Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. , 2003, BioTechniques.

[86]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[87]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[88]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[89]  Keji Zhao,et al.  Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes , 2002, Nature.

[90]  J. Mountz,et al.  Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy. , 2001, Gynecologic oncology.

[91]  N. Breslow,et al.  Clinical Presentation of Rhabdoid Tumors of the Kidney , 2001, Journal of pediatric hematology/oncology.

[92]  Meng Yang,et al.  In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis , 2000, Cancer Gene Therapy.

[93]  B J McNeil,et al.  Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. , 2000, Radiology.

[94]  W. Holzgreve,et al.  Characterization of an immortalized human granulosa cell line (COV434). , 2000, Molecular human reproduction.

[95]  H. Walt,et al.  Photodynamic therapy for the hypercalcemic type of the small cell carcinoma of the ovary in a mouse xenograft model. , 1999, Gynecologic oncology.

[96]  S. Florell,et al.  Ovarian small cell carcinoma of the hypercalcemic type in a 14 month old: the youngest reported case. , 1999, Medical and pediatric oncology.

[97]  Robert M Hoffman,et al.  A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer , 1998, Clinical & Experimental Metastasis.

[98]  M. Morgan,et al.  Clinical characteristics of clear cell carcinoma of the ovary. , 1998, Gynecologic oncology.

[99]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[100]  M. Sherman,et al.  Inhibin and Epithelial Membrane Antigen Immunohistochemistry Assist in the Diagnosis of Sex Cord‐Stromal Tumors and Provide Clues to the Histogenesis of Hypercalcemic Small Cell Carcinomas , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[101]  A. Roessner,et al.  Small cell carcinoma of the ovary, hypercalcemic type. A case report with immunohistochemical, ultrastructural and cytophotometric analysis and review of the literature. , 1997, General & diagnostic pathology.

[102]  M. Yaniv,et al.  Purification and biochemical heterogeneity of the mammalian SWI‐SNF complex. , 1996, The EMBO journal.

[103]  E. Partridge,et al.  Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). , 1996, Seminars in oncology.

[104]  J. Lamovec,et al.  Familial occurrence of small-cell carcinoma of the ovary. , 1995, Archives of pathology & laboratory medicine.

[105]  E. Oliva,et al.  Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Clinicopathological Analysis of 150 Cases , 1994, The American journal of surgical pathology.

[106]  R. Scully,et al.  Human parathyroid hormone‐related protein in ovarian small cell carcinoma. An immunohistochemical study , 1994, Cancer.

[107]  M. Chalfie,et al.  Green fluorescent protein as a marker for gene expression. , 1994, Science.

[108]  R. Hoffman,et al.  Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. , 1993, Anticancer research.

[109]  A. Talerman,et al.  Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide in the treatment of small cell carcinoma of the ovary , 1989, Cancer.

[110]  J. Nesland,et al.  Small Cell Carcinoma of the Ovary; A Report of Six Cases , 1988, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[111]  S. Krane,et al.  Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: A calcitonin‐responsive line derived from a rare tumor type , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[112]  I. Taylor,et al.  Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer. , 1985, British Journal of Cancer.

[113]  M. Carlson,et al.  Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. , 1984, Genetics.

[114]  I. Herskowitz,et al.  Five SWI genes are required for expression of the HO gene in yeast. , 1984, Journal of molecular biology.

[115]  D. Goldenberg,et al.  In vivo horizontal oncogenesis by a human tumor in nude mice. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[116]  H. Fox.  Tumors of the Ovary and Maldeveloped Gonads , 1981 .

[117]  M. Munsell,et al.  Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases. , 2016, Gynecologic oncology.

[118]  F. She,et al.  Establishment of and comparison between orthotopic xenograft and subcutaneous xenograft models of gallbladder carcinoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[119]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[120]  W. Weber,et al.  Anesthesia and other considerations for in vivo imaging of small animals. , 2008, ILAR journal.

[121]  Robert M. Hoffman,et al.  Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic , 2004, Investigational New Drugs.

[122]  J. Biegel,et al.  Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. , 1999, Cancer research.

[123]  R. Scully,et al.  Small cell carcinoma of the ovary with hypercalcemia: A report of eleven cases , 1982, Cancer.

[124]  B. Bystricky,et al.  Usage and Distribution for Commercial Purposes Requires Written Permission. Small Cell Carcinoma of the Ovary (hypercalcemic Type): Malignant Rhabdoid Tumor , 2022 .